Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Aftimos

Showing results (31-40 of 82) with videos related to

Pageof 9
Sort By:
Clinical Breast Cancer|June 9, 2016
Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G GeneAhmad Awada, Javier Cortés, Miguel Martín, et al.
JAMA Network Open|December 11, 2025
Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer PopulationLucas F van Schaik, Brigitte Maes, Pieter-Jan Volders, et al.
JCO Precision Oncology|July 6, 2026
Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision StudyLore Decoster, Philippe Aftimos, Sylvie Rottey, et al.
Cancer Chemotherapy and Pharmacology|December 10, 2015
A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumorsPatrick Schöffski, Philippe Aftimos, Herlinde Dumez, et al.
British Journal of Cancer|December 14, 2021
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumoursDebbie Robbrecht, Christiane Jungels, Morten Mau Sorensen, et al.
The Oncologist|June 10, 2026
Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancerJose Sandoval, Patrick Neven, Anna Emde, et al.
BMC Cancer|June 3, 2014
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN studyAmelie Deleporte, Marianne Paesmans, Camilo Garcia, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumoursPatrick Schöffski, Ahmad Awada, Anne-Marie de la Bigne, et al.
Oncotarget|December 2, 2016
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancerMarzia A Locatelli, Philippe Aftimos, E Claire Dees, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2016
Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trialPhilippe Aftimos, Laura Polastro, Lieveke Ameye, et al.
Pageof 9

Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Clinical Breast Cancer|June 9, 2016
Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G GeneAhmad Awada, Javier Cortés, Miguel Martín, et al.
JAMA Network Open|December 11, 2025
Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer PopulationLucas F van Schaik, Brigitte Maes, Pieter-Jan Volders, et al.
JCO Precision Oncology|July 6, 2026
Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision StudyLore Decoster, Philippe Aftimos, Sylvie Rottey, et al.
Cancer Chemotherapy and Pharmacology|December 10, 2015
A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumorsPatrick Schöffski, Philippe Aftimos, Herlinde Dumez, et al.
British Journal of Cancer|December 14, 2021
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumoursDebbie Robbrecht, Christiane Jungels, Morten Mau Sorensen, et al.
The Oncologist|June 10, 2026
Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancerJose Sandoval, Patrick Neven, Anna Emde, et al.
BMC Cancer|June 3, 2014
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN studyAmelie Deleporte, Marianne Paesmans, Camilo Garcia, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumoursPatrick Schöffski, Ahmad Awada, Anne-Marie de la Bigne, et al.
Oncotarget|December 2, 2016
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancerMarzia A Locatelli, Philippe Aftimos, E Claire Dees, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2016
Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trialPhilippe Aftimos, Laura Polastro, Lieveke Ameye, et al.
Pageof 9